A new era of personalized medicine began last fall when the U.S. and other countries gave the first-ever approvals to a treatment based on CRISPR gene editing: Casgevy, developed by Vertex and CRISPR Therapeutics, treats sickle cell, a genetic disorder that affects some 20 million globally. The pioneering treatment is expensive (the list price is $2.2 million), and may not be initially feasible in sub-Saharan Africa, where about 75% of people with sickle cell live. But by April, the first patients had started the treatment process. Vertex expects revenues to top $10 billion in 2024, largely powered by another remarkable drug, cystic fibrosis treatment Trikafta, which got FDA approval in 2019 and has transformed patients’ lives. CEO Reshma Kewalramani calls the historic sickle-cell breakthrough a beginning. “We are on the cusp of moving from…taking pills by mouth every day,” she says, “to potentially one-and-done therapies, where you have a procedure once and hopefully benefit for life.”
More Must-Reads from TIME
- Welcome to the Golden Age of Scams
- Introducing TIME's 2024 Latino Leaders
- How to Make an Argument That’s Actually Persuasive
- Did the Pandemic Break Our Brains?
- 33 True Crime Documentaries That Shaped the Genre
- The Ordained Rabbi Who Bought a Porn Company
- Why Gut Health Issues Are More Common in Women
- The 100 Most Influential People in AI 2024
Contact us at letters@time.com